Compare Amgen, Inc. (AMGN) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares TIPS Bond ETF — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while iShares TIPS Bond ETF trades at $108.13. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares TIPS Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | TIP | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Fixed Income |
52-Week High | $388.16 | $112.20 |
52-Week Low | $271.18 | $108.05 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TIP trades at $108.13 with minimal daily movement, showing a 0.01% gain. Technical indicators signal a bearish trend with moving averages unanimously negative, though oscillators remain neutral. The stock faces significant selling pressure with 17 sell signals versus 5 buy signals. Recent corporate actions include scheduled dividend payments of $1.28 in June 2026 and $1.06 in July 2026, providing income appeal despite the weak technical picture.
The outlook remains cautious given the bearish technical momentum and absence of current fundamental data. Dividend payments offer some support, but the stock requires monitoring for fundamental updates and potential technical reversal signals before establishing a bullish position. Market sentiment reflects broader bond market uncertainties and Federal Reserve policy concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
